Hosted on MSN
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback